CS246080B2 - Method of piperazine derivatives production - Google Patents
Method of piperazine derivatives production Download PDFInfo
- Publication number
- CS246080B2 CS246080B2 CS843680A CS368084A CS246080B2 CS 246080 B2 CS246080 B2 CS 246080B2 CS 843680 A CS843680 A CS 843680A CS 368084 A CS368084 A CS 368084A CS 246080 B2 CS246080 B2 CS 246080B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- piperazine
- formula
- aminocarbonylmethyl
- hydroxypropyl
- methoxyphenoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 60
- 150000004885 piperazines Chemical class 0.000 title claims description 16
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 5
- -1 aminocarbonyl-methyl Chemical group 0.000 claims abstract description 242
- 150000001875 compounds Chemical class 0.000 claims abstract description 154
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- 239000002253 acid Substances 0.000 claims abstract description 36
- 239000001257 hydrogen Substances 0.000 claims abstract description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 23
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 229910052717 sulfur Chemical group 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims abstract description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 3
- 150000002431 hydrogen Chemical group 0.000 claims abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 195
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 59
- 238000002360 preparation method Methods 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 239000012458 free base Substances 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 241001387976 Pera Species 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 9
- 206010003119 arrhythmia Diseases 0.000 abstract description 8
- 230000006793 arrhythmia Effects 0.000 abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 208000010125 myocardial infarction Diseases 0.000 abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 3
- 239000011593 sulfur Chemical group 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 201000001068 Prinzmetal angina Diseases 0.000 abstract 1
- 230000003185 calcium uptake Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 150000001448 anilines Chemical class 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- UKFTXWKNVSVVCJ-UHFFFAOYSA-N 2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol;hydron;dichloride Chemical compound Cl.Cl.NNC1=CC=C(N(CCO)CCO)N=N1 UKFTXWKNVSVVCJ-UHFFFAOYSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 7
- UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 6
- RJNVSQLNEALZLC-UHFFFAOYSA-N 2-[(2-methoxyphenoxy)methyl]oxirane Chemical compound COC1=CC=CC=C1OCC1OC1 RJNVSQLNEALZLC-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 150000001805 chlorine compounds Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- HVPPJURUTODQOY-UHFFFAOYSA-N 1-(2-methoxyphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CCNCC1 HVPPJURUTODQOY-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960001867 guaiacol Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- NLGKRVNANIZGNI-UHFFFAOYSA-N n,2,6-trimethylaniline Chemical compound CNC1=C(C)C=CC=C1C NLGKRVNANIZGNI-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 3
- JFVISFDPXDYDBD-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfanylmethyl]oxirane Chemical compound C1=CC(C)=CC=C1SCC1OC1 JFVISFDPXDYDBD-UHFFFAOYSA-N 0.000 description 3
- VONWPEXRCLHKRJ-UHFFFAOYSA-N 2-chloro-n-phenylacetamide Chemical compound ClCC(=O)NC1=CC=CC=C1 VONWPEXRCLHKRJ-UHFFFAOYSA-N 0.000 description 3
- JEQDSBVHLKBEIZ-UHFFFAOYSA-N 2-chloropropanoyl chloride Chemical compound CC(Cl)C(Cl)=O JEQDSBVHLKBEIZ-UHFFFAOYSA-N 0.000 description 3
- WBRPQQSADOCKCH-UHFFFAOYSA-N 2-methylsulfanylaniline Chemical compound CSC1=CC=CC=C1N WBRPQQSADOCKCH-UHFFFAOYSA-N 0.000 description 3
- ZWTZHHHSRDUVRT-UHFFFAOYSA-N 2-methylsulfonylphenol Chemical compound CS(=O)(=O)C1=CC=CC=C1O ZWTZHHHSRDUVRT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960001413 acetanilide Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- XHMRDGZJJLOGLX-UHFFFAOYSA-N 1-[4-(oxiran-2-ylmethoxy)phenyl]butan-1-one Chemical compound C1=CC(C(=O)CCC)=CC=C1OCC1OC1 XHMRDGZJJLOGLX-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 2
- NTMMJCXPHYKNSP-UHFFFAOYSA-N 2-[(2,4-dichlorophenoxy)methyl]oxirane Chemical compound ClC1=CC(Cl)=CC=C1OCC1OC1 NTMMJCXPHYKNSP-UHFFFAOYSA-N 0.000 description 2
- IYFFPRFMOMGBGB-UHFFFAOYSA-N 2-[(2-chlorophenoxy)methyl]oxirane Chemical compound ClC1=CC=CC=C1OCC1OC1 IYFFPRFMOMGBGB-UHFFFAOYSA-N 0.000 description 2
- KFUSXMDYOPXKKT-UHFFFAOYSA-N 2-[(2-methylphenoxy)methyl]oxirane Chemical compound CC1=CC=CC=C1OCC1OC1 KFUSXMDYOPXKKT-UHFFFAOYSA-N 0.000 description 2
- OOGKHYDQPVVTOR-UHFFFAOYSA-N 2-[(4-butylsulfinylphenoxy)methyl]oxirane Chemical compound C1=CC(S(=O)CCCC)=CC=C1OCC1OC1 OOGKHYDQPVVTOR-UHFFFAOYSA-N 0.000 description 2
- AVWGFHZLPMLKBL-UHFFFAOYSA-N 2-[(4-methoxyphenoxy)methyl]oxirane Chemical compound C1=CC(OC)=CC=C1OCC1OC1 AVWGFHZLPMLKBL-UHFFFAOYSA-N 0.000 description 2
- CUFXMPWHOWYNSO-UHFFFAOYSA-N 2-[(4-methylphenoxy)methyl]oxirane Chemical compound C1=CC(C)=CC=C1OCC1OC1 CUFXMPWHOWYNSO-UHFFFAOYSA-N 0.000 description 2
- NXPYKVZYIMYBPY-UHFFFAOYSA-N 2-[(4-methylsulfonylphenoxy)methyl]oxirane Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OCC1OC1 NXPYKVZYIMYBPY-UHFFFAOYSA-N 0.000 description 2
- TTZNROCQNQYRHZ-UHFFFAOYSA-N 2-[2-(2,6-dimethylphenyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1C1N(CC(N)=O)CCNC1 TTZNROCQNQYRHZ-UHFFFAOYSA-N 0.000 description 2
- XHAHQRCYHBGBIA-UHFFFAOYSA-N 2-[4-(2-hydroxy-3-phenylsulfanylpropyl)piperazin-1-yl]-n-phenylacetamide Chemical compound C1CN(CC(=O)NC=2C=CC=CC=2)CCN1CC(O)CSC1=CC=CC=C1 XHAHQRCYHBGBIA-UHFFFAOYSA-N 0.000 description 2
- HUGIVMNPKYXXRA-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(4-methylphenyl)sulfanylpropyl]piperazin-1-yl]-n-phenylacetamide Chemical compound C1=CC(C)=CC=C1SCC(O)CN1CCN(CC(=O)NC=2C=CC=CC=2)CC1 HUGIVMNPKYXXRA-UHFFFAOYSA-N 0.000 description 2
- WXOZCZASTWJRKQ-UHFFFAOYSA-N 2-[4-[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 WXOZCZASTWJRKQ-UHFFFAOYSA-N 0.000 description 2
- PQVJYIRPKLGJEW-UHFFFAOYSA-N 2-[4-[3-(2-acetylphenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 PQVJYIRPKLGJEW-UHFFFAOYSA-N 0.000 description 2
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 2
- WYVJWHBYNAQOHK-UHFFFAOYSA-N 2-chlorohexanoyl chloride Chemical compound CCCCC(Cl)C(Cl)=O WYVJWHBYNAQOHK-UHFFFAOYSA-N 0.000 description 2
- OGUIFELBZNMXGH-UHFFFAOYSA-N 2-methylsulfinylaniline Chemical compound CS(=O)C1=CC=CC=C1N OGUIFELBZNMXGH-UHFFFAOYSA-N 0.000 description 2
- VMTHIQRJDDCEQD-UHFFFAOYSA-N 2-methylsulfinylphenol Chemical compound CS(=O)C1=CC=CC=C1O VMTHIQRJDDCEQD-UHFFFAOYSA-N 0.000 description 2
- AUSRSVRJOXYXMI-UHFFFAOYSA-N 2-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC=C1N AUSRSVRJOXYXMI-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 2
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- SAEMTJJSDYSGLS-UHFFFAOYSA-N C(CCC)C1=CC=C(SCC2CO2)C=C1 Chemical compound C(CCC)C1=CC=C(SCC2CO2)C=C1 SAEMTJJSDYSGLS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- SMRBHWZUORIRJZ-UHFFFAOYSA-N [1-[4-[2-(2,6-dimethylanilino)-2-oxoethyl]piperazin-1-yl]-3-(2-methoxyphenoxy)propan-2-yl] dodecanoate Chemical compound C1CN(CC(=O)NC=2C(=CC=CC=2C)C)CCN1CC(OC(=O)CCCCCCCCCCC)COC1=CC=CC=C1OC SMRBHWZUORIRJZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- RJNSNFZXAZXOFX-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;hydron;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 RJNSNFZXAZXOFX-UHFFFAOYSA-N 0.000 description 2
- DUTUMWSUQJNLIS-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC(Cl)=CC=2)CC1 DUTUMWSUQJNLIS-UHFFFAOYSA-N 0.000 description 2
- UMHATKUMNAUAPM-UHFFFAOYSA-N n-butyl-2,6-dimethylaniline Chemical compound CCCCNC1=C(C)C=CC=C1C UMHATKUMNAUAPM-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 description 1
- BRLQWZUYTZBJKN-VKHMYHEASA-N (-)-Epichlorohydrin Chemical compound ClC[C@H]1CO1 BRLQWZUYTZBJKN-VKHMYHEASA-N 0.000 description 1
- RJNVSQLNEALZLC-MRVPVSSYSA-N (2r)-2-[(2-methoxyphenoxy)methyl]oxirane Chemical compound COC1=CC=CC=C1OC[C@@H]1OC1 RJNVSQLNEALZLC-MRVPVSSYSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RJNVSQLNEALZLC-QMMMGPOBSA-N (2s)-2-[(2-methoxyphenoxy)methyl]oxirane Chemical compound COC1=CC=CC=C1OC[C@H]1OC1 RJNVSQLNEALZLC-QMMMGPOBSA-N 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- QLRBNEZOQPLERN-UHFFFAOYSA-N (sulfonylamino)benzene Chemical class O=S(=O)=NC1=CC=CC=C1 QLRBNEZOQPLERN-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XRSKRSVTUVLURN-UHFFFAOYSA-N 1,3-benzodioxol-4-ol Chemical class OC1=CC=CC2=C1OCO2 XRSKRSVTUVLURN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LXGBDGCDSQBZQA-UHFFFAOYSA-N 1-(2-bromophenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1CNCCN1CC(O)COC1=CC=CC=C1Br LXGBDGCDSQBZQA-UHFFFAOYSA-N 0.000 description 1
- HOKMUPHZNVOXDG-UHFFFAOYSA-N 1-(2-chlorophenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1CNCCN1CC(O)COC1=CC=CC=C1Cl HOKMUPHZNVOXDG-UHFFFAOYSA-N 0.000 description 1
- DKUQBZHTHQFDKN-UHFFFAOYSA-N 1-(2-methylphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound CC1=CC=CC=C1OCC(O)CN1CCNCC1 DKUQBZHTHQFDKN-UHFFFAOYSA-N 0.000 description 1
- ZKWMPGGXDJUCEM-UHFFFAOYSA-N 1-(3,4-dichloro-2,6-dimethylphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound CC1=CC(Cl)=C(Cl)C(C)=C1OCC(O)CN1CCNCC1 ZKWMPGGXDJUCEM-UHFFFAOYSA-N 0.000 description 1
- LOHBUGASUBABIT-UHFFFAOYSA-N 1-(4-methoxyphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1=CC(OC)=CC=C1OCC(O)CN1CCNCC1 LOHBUGASUBABIT-UHFFFAOYSA-N 0.000 description 1
- XVLAXWBXNMSNFV-UHFFFAOYSA-N 1-(4-methylphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1=CC(C)=CC=C1OCC(O)CN1CCNCC1 XVLAXWBXNMSNFV-UHFFFAOYSA-N 0.000 description 1
- XVWDSJNCJWXBMF-UHFFFAOYSA-N 1-(4-methylsulfinylphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1=CC(S(=O)C)=CC=C1OCC(O)CN1CCNCC1 XVWDSJNCJWXBMF-UHFFFAOYSA-N 0.000 description 1
- YKMHIWFFRSBIPM-UHFFFAOYSA-N 1-(4-methylsulfonylphenoxy)-3-piperazin-1-ylpropan-2-ol Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OCC(O)CN1CCNCC1 YKMHIWFFRSBIPM-UHFFFAOYSA-N 0.000 description 1
- XMNKXKQWWJVLPH-UHFFFAOYSA-N 1-[2-(2-hydroxy-3-piperazin-1-ylpropoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CCNCC1 XMNKXKQWWJVLPH-UHFFFAOYSA-N 0.000 description 1
- VCJHWSHVJVUYQC-UHFFFAOYSA-N 1-[2-(oxiran-2-ylmethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC1OC1 VCJHWSHVJVUYQC-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- NPHKGEYJZVUKKB-UHFFFAOYSA-N 1-phenoxy-3-piperazin-2-ylpropan-2-ol Chemical group C1NCCNC1CC(O)COC1=CC=CC=C1 NPHKGEYJZVUKKB-UHFFFAOYSA-N 0.000 description 1
- GTXFVBWSAJDVIA-UHFFFAOYSA-N 1-piperazin-1-yl-3-(2,3,4,5-tetrabromophenoxy)propan-2-ol Chemical compound C1CNCCN1CC(O)COC1=CC(Br)=C(Br)C(Br)=C1Br GTXFVBWSAJDVIA-UHFFFAOYSA-N 0.000 description 1
- OAKMCUCHYYGJOU-UHFFFAOYSA-N 1-piperazin-1-yl-3-(3,4,5-trimethoxyphenoxy)propan-2-ol Chemical compound COC1=C(OC)C(OC)=CC(OCC(O)CN2CCNCC2)=C1 OAKMCUCHYYGJOU-UHFFFAOYSA-N 0.000 description 1
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- KUFFULVDNCHOFZ-UHFFFAOYSA-N 2,4-xylenol Chemical compound CC1=CC=C(O)C(C)=C1 KUFFULVDNCHOFZ-UHFFFAOYSA-N 0.000 description 1
- CILPHQCEVYJUDN-UHFFFAOYSA-N 2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetic acid Chemical compound CC(C)C1CCC(C)CC1OCC(O)=O CILPHQCEVYJUDN-UHFFFAOYSA-N 0.000 description 1
- SLWOPZBLNKPZCQ-UHFFFAOYSA-N 2-(naphthalen-1-ylmethyl)oxirane Chemical compound C=1C=CC2=CC=CC=C2C=1CC1CO1 SLWOPZBLNKPZCQ-UHFFFAOYSA-N 0.000 description 1
- BIJYXIOVXFBJEP-UHFFFAOYSA-N 2-(oxiran-2-ylmethoxy)benzonitrile Chemical compound N#CC1=CC=CC=C1OCC1OC1 BIJYXIOVXFBJEP-UHFFFAOYSA-N 0.000 description 1
- MYBWNWNBXBBZKW-UHFFFAOYSA-N 2-(phenylsulfanylmethyl)oxirane Chemical compound C1OC1CSC1=CC=CC=C1 MYBWNWNBXBBZKW-UHFFFAOYSA-N 0.000 description 1
- BHNQDTSAZVYCHD-UHFFFAOYSA-N 2-[(2,3,4,5-tetrabromophenoxy)methyl]oxirane Chemical compound BrC1=C(Br)C(Br)=CC(OCC2OC2)=C1Br BHNQDTSAZVYCHD-UHFFFAOYSA-N 0.000 description 1
- AYVQIRLANZOASX-UHFFFAOYSA-N 2-[(2,4-dimethylphenoxy)methyl]oxirane Chemical compound CC1=CC(C)=CC=C1OCC1OC1 AYVQIRLANZOASX-UHFFFAOYSA-N 0.000 description 1
- CFPYDAOUKFUDEY-UHFFFAOYSA-N 2-[(2-bromophenoxy)methyl]oxirane Chemical compound BrC1=CC=CC=C1OCC1OC1 CFPYDAOUKFUDEY-UHFFFAOYSA-N 0.000 description 1
- QCILLASWZBODND-UHFFFAOYSA-N 2-[(3,4,5-trichlorophenoxy)methyl]oxirane Chemical compound ClC1=C(Cl)C(Cl)=CC(OCC2OC2)=C1 QCILLASWZBODND-UHFFFAOYSA-N 0.000 description 1
- CTDYAEXIALDILK-UHFFFAOYSA-N 2-[(3,4-dichloro-2,6-dimethylphenoxy)methyl]oxirane Chemical compound CC1=CC(Cl)=C(Cl)C(C)=C1OCC1OC1 CTDYAEXIALDILK-UHFFFAOYSA-N 0.000 description 1
- NKOFDOIVCXZSNV-UHFFFAOYSA-N 2-[(3,4-dichloro-5-methylphenoxy)methyl]oxirane Chemical compound ClC1=C(Cl)C(C)=CC(OCC2OC2)=C1 NKOFDOIVCXZSNV-UHFFFAOYSA-N 0.000 description 1
- VOZLOJMPDJOVQK-UHFFFAOYSA-N 2-[(3-chloro-4-methylphenoxy)methyl]oxirane Chemical compound C1=C(Cl)C(C)=CC=C1OCC1OC1 VOZLOJMPDJOVQK-UHFFFAOYSA-N 0.000 description 1
- WYAFQPYCJBLWAS-UHFFFAOYSA-N 2-[(3-methylphenoxy)methyl]oxirane Chemical compound CC1=CC=CC(OCC2OC2)=C1 WYAFQPYCJBLWAS-UHFFFAOYSA-N 0.000 description 1
- DXEHULHXWHEJJD-UHFFFAOYSA-N 2-[(4-butylphenoxy)methyl]oxirane Chemical compound C1=CC(CCCC)=CC=C1OCC1OC1 DXEHULHXWHEJJD-UHFFFAOYSA-N 0.000 description 1
- VSXUYJWPMDYWQA-UHFFFAOYSA-N 2-[(4-butylsulfonylphenoxy)methyl]oxirane Chemical compound C1=CC(S(=O)(=O)CCCC)=CC=C1OCC1OC1 VSXUYJWPMDYWQA-UHFFFAOYSA-N 0.000 description 1
- OZPPORXDIRZZTA-UHFFFAOYSA-N 2-[(4-chloro-3-methoxy-5-methylphenoxy)methyl]oxirane Chemical compound CC1=C(Cl)C(OC)=CC(OCC2OC2)=C1 OZPPORXDIRZZTA-UHFFFAOYSA-N 0.000 description 1
- KSLSZOOZWRMSAP-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]oxirane Chemical compound C1=CC(Cl)=CC=C1OCC1OC1 KSLSZOOZWRMSAP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DUSBGDBNUOUEHK-UHFFFAOYSA-N 2-[4-(2-hydroxy-3-phenylsulfanylpropyl)piperazin-1-yl]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CN(CC1)CCN1CC(O)CSC1=CC=CC=C1 DUSBGDBNUOUEHK-UHFFFAOYSA-N 0.000 description 1
- SOGKXLVYZZXFTN-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound C1=CC(CC(=O)N)=CC=C1OCC1OC1 SOGKXLVYZZXFTN-UHFFFAOYSA-N 0.000 description 1
- BYJJVKCFJSEXFI-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-(2,4,6-trimethylphenyl)acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC(C)=CC=2C)C)CC1 BYJJVKCFJSEXFI-UHFFFAOYSA-N 0.000 description 1
- PNSQEIFQZFQHNY-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-(4-methylphenyl)acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC(C)=CC=2)CC1 PNSQEIFQZFQHNY-UHFFFAOYSA-N 0.000 description 1
- BBTNTAFLKVTHJR-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC(=CC=2)C(F)(F)F)CC1 BBTNTAFLKVTHJR-UHFFFAOYSA-N 0.000 description 1
- YPOAZESPSNWHHN-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-phenylacetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC=CC=2)CC1 YPOAZESPSNWHHN-UHFFFAOYSA-N 0.000 description 1
- BKSRYWVKXOAVOZ-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(2-methylphenoxy)propyl]piperazin-1-yl]-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC(=CC=2)C(F)(F)F)CC1 BKSRYWVKXOAVOZ-UHFFFAOYSA-N 0.000 description 1
- DSQCYSBBICCRDE-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(3-methoxyphenoxy)propyl]piperazin-1-yl]-n-[4-(2-methylpropyl)phenyl]acetamide Chemical compound COC1=CC=CC(OCC(O)CN2CCN(CC(=O)NC=3C=CC(CC(C)C)=CC=3)CC2)=C1 DSQCYSBBICCRDE-UHFFFAOYSA-N 0.000 description 1
- MJAKVBYNYXHPHD-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(4-methoxyphenoxy)propyl]piperazin-1-yl]-n-(2,4,6-trimethylphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC(C)=CC=2C)C)CC1 MJAKVBYNYXHPHD-UHFFFAOYSA-N 0.000 description 1
- BJEYHUDJQMPDFQ-UHFFFAOYSA-N 2-[4-[2-hydroxy-3-(4-methoxyphenoxy)propyl]piperazin-1-yl]-n-phenylacetamide Chemical compound C1=CC(OC)=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=CC=CC=2)CC1 BJEYHUDJQMPDFQ-UHFFFAOYSA-N 0.000 description 1
- KXRNKQCICNDNSS-UHFFFAOYSA-N 2-[4-[3-(2-chlorophenoxy)-2-hydroxypropyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide Chemical compound ClC1=C(OCC(CN2CCN(CC2)CC(=O)NC2=C(C=CC=C2C)C)O)C=CC=C1 KXRNKQCICNDNSS-UHFFFAOYSA-N 0.000 description 1
- KWHMHVYQQSZZDX-UHFFFAOYSA-N 2-[4-[3-(2-cyanophenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C(=CC=CC=2)C#N)CC1 KWHMHVYQQSZZDX-UHFFFAOYSA-N 0.000 description 1
- KTRMOLNHHIJDMP-UHFFFAOYSA-N 2-[4-[3-(3,4-dichloro-2-methylphenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C(=C(Cl)C(Cl)=CC=2)C)CC1 KTRMOLNHHIJDMP-UHFFFAOYSA-N 0.000 description 1
- HAAFBNRNBBBQMA-UHFFFAOYSA-N 2-[4-[3-(3-chlorophenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=C(Cl)C=CC=2)CC1 HAAFBNRNBBBQMA-UHFFFAOYSA-N 0.000 description 1
- FEPVZRZOPUGNQG-UHFFFAOYSA-N 2-[4-[3-(4-butylsulfinylphenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound C1=CC(S(=O)CCCC)=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 FEPVZRZOPUGNQG-UHFFFAOYSA-N 0.000 description 1
- LUQUGXKYXBJMAR-UHFFFAOYSA-N 2-[4-[3-(4-butylsulfonylphenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound C1=CC(S(=O)(=O)CCCC)=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 LUQUGXKYXBJMAR-UHFFFAOYSA-N 0.000 description 1
- MJUYBXOZPRMHBH-UHFFFAOYSA-N 2-[4-[3-[4-[2-(2,6-dimethylanilino)-2-oxoethyl]piperazin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C=CC(CC(N)=O)=CC=2)CC1 MJUYBXOZPRMHBH-UHFFFAOYSA-N 0.000 description 1
- GYOFXQNABVOHIB-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenoxy]methyl]oxirane Chemical compound C1=CC(C(F)(F)F)=CC=C1OCC1OC1 GYOFXQNABVOHIB-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- HPSCXFOQUFPEPE-UHFFFAOYSA-N 2-chloro-5-methylaniline Chemical compound CC1=CC=C(Cl)C(N)=C1 HPSCXFOQUFPEPE-UHFFFAOYSA-N 0.000 description 1
- NXBPLYWSINFZHW-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)-n-methylacetamide Chemical compound ClCC(=O)N(C)C1=C(C)C=CC=C1C NXBPLYWSINFZHW-UHFFFAOYSA-N 0.000 description 1
- FPQQSNUTBWFFLB-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CCl FPQQSNUTBWFFLB-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- RVBUZBPJAGZHSQ-UHFFFAOYSA-N 2-chlorobutanoic acid Chemical compound CCC(Cl)C(O)=O RVBUZBPJAGZHSQ-UHFFFAOYSA-N 0.000 description 1
- KVQJVAOMYWTLEO-UHFFFAOYSA-N 2-chlorobutanoyl chloride Chemical compound CCC(Cl)C(Cl)=O KVQJVAOMYWTLEO-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- UUSSXQBVAQWMQQ-UHFFFAOYSA-N 3,4-dichloro-2,5-dimethylphenol Chemical compound CC1=CC(O)=C(C)C(Cl)=C1Cl UUSSXQBVAQWMQQ-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 1
- PIURGOSBNJWEHN-UHFFFAOYSA-N 3-[4-(2-hydroxy-3-phenoxypropyl)piperazin-1-yl]-n-methyl-n-phenylpropanamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CCN(CC1)CCN1CC(O)COC1=CC=CC=C1 PIURGOSBNJWEHN-UHFFFAOYSA-N 0.000 description 1
- HZMQSIUOJRUIRY-UHFFFAOYSA-N 3-[4-(2-hydroxy-3-phenoxypropyl)piperazin-1-yl]-n-phenylpropanamide Chemical compound C1CN(CCC(=O)NC=2C=CC=CC=2)CCN1CC(O)COC1=CC=CC=C1 HZMQSIUOJRUIRY-UHFFFAOYSA-N 0.000 description 1
- QWYWISJUPBZXFP-UHFFFAOYSA-N 3-[4-(2-hydroxy-3-phenylsulfanylpropyl)piperazin-1-yl]-n-phenylpropanamide Chemical compound C1CN(CCC(=O)NC=2C=CC=CC=2)CCN1CC(O)CSC1=CC=CC=C1 QWYWISJUPBZXFP-UHFFFAOYSA-N 0.000 description 1
- UQVCSFDUZLYKDX-UHFFFAOYSA-N 3-[4-[3-(4-chlorophenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-methyl-n-phenylpropanamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CCN(CC1)CCN1CC(O)COC1=CC=C(Cl)C=C1 UQVCSFDUZLYKDX-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- LNYPMVHBRZGZLK-UHFFFAOYSA-N 3-chloro-2,4,6-trimethylaniline Chemical compound CC1=CC(C)=C(Cl)C(C)=C1N LNYPMVHBRZGZLK-UHFFFAOYSA-N 0.000 description 1
- FRXJYUFHAXXSAL-UHFFFAOYSA-N 3-chloro-n-phenylpropanamide Chemical compound ClCCC(=O)NC1=CC=CC=C1 FRXJYUFHAXXSAL-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- WRXOZRLZDJAYDR-UHFFFAOYSA-N 3-methylbenzenethiol Chemical group CC1=CC=CC(S)=C1 WRXOZRLZDJAYDR-UHFFFAOYSA-N 0.000 description 1
- FLVCXTAJLMMZHF-UHFFFAOYSA-N 4-(dibutylamino)phenol Chemical compound CCCCN(CCCC)C1=CC=C(O)C=C1 FLVCXTAJLMMZHF-UHFFFAOYSA-N 0.000 description 1
- IQUGXLWZJMTGJL-UHFFFAOYSA-N 4-[4-[3-(4-chlorophenoxy)-2-hydroxypropyl]piperazin-1-yl]-n-methyl-n-phenylbutanamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CCCN(CC1)CCN1CC(O)COC1=CC=C(Cl)C=C1 IQUGXLWZJMTGJL-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- UBRIHZOFEJHMIT-UHFFFAOYSA-N 4-butoxyaniline Chemical compound CCCCOC1=CC=C(N)C=C1 UBRIHZOFEJHMIT-UHFFFAOYSA-N 0.000 description 1
- OGIQUQKNJJTLSZ-UHFFFAOYSA-N 4-butylaniline Chemical compound CCCCC1=CC=C(N)C=C1 OGIQUQKNJJTLSZ-UHFFFAOYSA-N 0.000 description 1
- LPOAFPIPCHFMQF-UHFFFAOYSA-N 4-butylsulfanylaniline Chemical compound CCCCSC1=CC=C(N)C=C1 LPOAFPIPCHFMQF-UHFFFAOYSA-N 0.000 description 1
- PCJCEUQTJBKDGH-UHFFFAOYSA-N 4-butylsulfinylaniline Chemical compound CCCCS(=O)C1=CC=C(N)C=C1 PCJCEUQTJBKDGH-UHFFFAOYSA-N 0.000 description 1
- HBNSCBAEYVWNNV-UHFFFAOYSA-N 4-butylsulfonylaniline Chemical compound CCCCS(=O)(=O)C1=CC=C(N)C=C1 HBNSCBAEYVWNNV-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- MNVMYTVDDOXZLS-UHFFFAOYSA-N 4-methoxyguaiacol Natural products COC1=CC=C(O)C(OC)=C1 MNVMYTVDDOXZLS-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- SULNLNVYOGZGNK-UHFFFAOYSA-N 4-methylsulfinylaniline Chemical compound CS(=O)C1=CC=C(N)C=C1 SULNLNVYOGZGNK-UHFFFAOYSA-N 0.000 description 1
- XJEVFFNOMKXBLU-UHFFFAOYSA-N 4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1 XJEVFFNOMKXBLU-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JYIQIWJYPAFJSJ-UHFFFAOYSA-N CC1=C(C(=CC=C1)C)N(C)C(=O)CCCCCN2CCN(CC2)CC(COC3=CC=CC=C3OC)O Chemical compound CC1=C(C(=CC=C1)C)N(C)C(=O)CCCCCN2CCN(CC2)CC(COC3=CC=CC=C3OC)O JYIQIWJYPAFJSJ-UHFFFAOYSA-N 0.000 description 1
- CZGVWESRLJEPLF-UHFFFAOYSA-N CC1=CC=C(SCC(CN2CCN(CC2)CC(=O)NC2=CC=C(C=C2)CCCC)O)C=C1 Chemical compound CC1=CC=C(SCC(CN2CCN(CC2)CC(=O)NC2=CC=C(C=C2)CCCC)O)C=C1 CZGVWESRLJEPLF-UHFFFAOYSA-N 0.000 description 1
- OTFYSLZYQGFRBV-UHFFFAOYSA-N COC1=C(OCC(CN2CCN(CC2)CC(=O)NC2=C(C=CC=C2)OC2=CC=C(C=C2)OC)O)C=CC=C1 Chemical compound COC1=C(OCC(CN2CCN(CC2)CC(=O)NC2=C(C=CC=C2)OC2=CC=C(C=C2)OC)O)C=CC=C1 OTFYSLZYQGFRBV-UHFFFAOYSA-N 0.000 description 1
- WMHRAHPELVJISM-UHFFFAOYSA-N COC1=C(OCC(CN2CCN(CC2)CC(=O)NC2=CC(=C(C(=C2)OC)OC)OC)O)C=CC=C1 Chemical compound COC1=C(OCC(CN2CCN(CC2)CC(=O)NC2=CC(=C(C(=C2)OC)OC)OC)O)C=CC=C1 WMHRAHPELVJISM-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- GQXQGYJWZKJUBI-UHFFFAOYSA-N FC(C(OC(C(C(C(C1(F)Br)(Br)Br)(Cl)Br)(N2F)F)(C1(F)Cl)F)(S2(Br)(Br)Br)Br)(F)F Chemical class FC(C(OC(C(C(C(C1(F)Br)(Br)Br)(Cl)Br)(N2F)F)(C1(F)Cl)F)(S2(Br)(Br)Br)Br)(F)F GQXQGYJWZKJUBI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- ANUKMCRRWRBFQX-UHFFFAOYSA-N N-(3,5-dimethoxyphenyl)-2-[4-[2-hydroxy-3-(4-methylphenyl)sulfanylpropyl]piperazin-1-yl]acetamide Chemical compound CC1=CC=C(SCC(CN2CCN(CC2)CC(=O)NC2=CC(=CC(=C2)OC)OC)O)C=C1 ANUKMCRRWRBFQX-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AGUVPEIWFJYRAR-UHFFFAOYSA-N [1-[4-[2-(2,6-dimethylanilino)-2-oxoethyl]piperazin-1-yl]-3-(2-methoxyphenoxy)propan-2-yl] butanoate Chemical compound C1CN(CC(=O)NC=2C(=CC=CC=2C)C)CCN1CC(OC(=O)CCC)COC1=CC=CC=C1OC AGUVPEIWFJYRAR-UHFFFAOYSA-N 0.000 description 1
- HIMISPAEUMAIIF-UHFFFAOYSA-N [1-[4-[2-(2,6-dimethylanilino)-2-oxoethyl]piperazin-1-yl]-3-(2-methoxyphenoxy)propan-2-yl] hexanoate Chemical compound C1CN(CC(=O)NC=2C(=CC=CC=2C)C)CCN1CC(OC(=O)CCCCC)COC1=CC=CC=C1OC HIMISPAEUMAIIF-UHFFFAOYSA-N 0.000 description 1
- KECLYWKKMFOZBI-UHFFFAOYSA-N [Cl].CC(Cl)=O Chemical compound [Cl].CC(Cl)=O KECLYWKKMFOZBI-UHFFFAOYSA-N 0.000 description 1
- RDATWFFCODFLLB-SEPHDYHBSA-M [Na+].[Cl-].OC(=O)\C=C\C(O)=O Chemical compound [Na+].[Cl-].OC(=O)\C=C\C(O)=O RDATWFFCODFLLB-SEPHDYHBSA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000866 anti-infarct Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UETQVDZZPKAQIC-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl.Cl UETQVDZZPKAQIC-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- NWADXBLMWHFGGU-UHFFFAOYSA-N dodecanoic anhydride Chemical compound CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC NWADXBLMWHFGGU-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- SOOARYARZPXNAL-UHFFFAOYSA-N methyl-thiophenol Natural products CSC1=CC=CC=C1O SOOARYARZPXNAL-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VJOVOQVIGOALEP-UHFFFAOYSA-N n,n-dibutyl-4-(oxiran-2-ylmethoxy)aniline Chemical compound C1=CC(N(CCCC)CCCC)=CC=C1OCC1OC1 VJOVOQVIGOALEP-UHFFFAOYSA-N 0.000 description 1
- PWGLQVOHVNHXDW-UHFFFAOYSA-N n-(2,4-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC(C)=CC=2)C)CC1 PWGLQVOHVNHXDW-UHFFFAOYSA-N 0.000 description 1
- LAOXTTWMCIWEEV-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=C(C)C=2)C)CC1 LAOXTTWMCIWEEV-UHFFFAOYSA-N 0.000 description 1
- OCJFGVQKNABUCQ-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2Cl)Cl)CC1 OCJFGVQKNABUCQ-UHFFFAOYSA-N 0.000 description 1
- FVEDRKKDWXSQKA-UHFFFAOYSA-N n-(2,6-diethoxyphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-methylacetamide Chemical compound CCOC1=CC=CC(OCC)=C1N(C)C(=O)CN1CCN(CC(O)COC=2C(=CC=CC=2)OC)CC1 FVEDRKKDWXSQKA-UHFFFAOYSA-N 0.000 description 1
- FWQRNKDNWPGYON-UHFFFAOYSA-N n-(2,6-diethoxyphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound CCOC1=CC=CC(OCC)=C1NC(=O)CN1CCN(CC(O)COC=2C(=CC=CC=2)OC)CC1 FWQRNKDNWPGYON-UHFFFAOYSA-N 0.000 description 1
- BGUDHVYNZSCCFC-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-naphthalen-1-yloxypropyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 BGUDHVYNZSCCFC-UHFFFAOYSA-N 0.000 description 1
- YFEITPULTUOMHB-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methylphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound CC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 YFEITPULTUOMHB-UHFFFAOYSA-N 0.000 description 1
- NPQJSVVNIVITDC-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-propan-2-yloxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound CC(C)OC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 NPQJSVVNIVITDC-UHFFFAOYSA-N 0.000 description 1
- IMZMNTQZVWHTMZ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(3-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC(OCC(O)CN2CCN(CC(=O)NC=3C(=CC=CC=3C)C)CC2)=C1 IMZMNTQZVWHTMZ-UHFFFAOYSA-N 0.000 description 1
- VPFQSHNJPXAQEY-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-3-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]-n-methylpropanamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CCC(=O)N(C)C=2C(=CC=CC=2C)C)CC1 VPFQSHNJPXAQEY-UHFFFAOYSA-N 0.000 description 1
- IEECBVYNQUZYAQ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-3-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]propanamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CCC(=O)NC=2C(=CC=CC=2C)C)CC1 IEECBVYNQUZYAQ-UHFFFAOYSA-N 0.000 description 1
- RGOAAQNQAKMSDT-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-6-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]hexanamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CCCCCC(=O)NC=2C(=CC=CC=2C)C)CC1 RGOAAQNQAKMSDT-UHFFFAOYSA-N 0.000 description 1
- KGEIPOKEZWHRHH-UHFFFAOYSA-N n-(2-chloro-5-methylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=C(C)C=2)Cl)CC1 KGEIPOKEZWHRHH-UHFFFAOYSA-N 0.000 description 1
- AISXZHFVCOUVAV-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=C(Cl)C(Cl)=CC=2)CC1 AISXZHFVCOUVAV-UHFFFAOYSA-N 0.000 description 1
- SHHVHOCXTIVHRU-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)CN1CCN(CC(O)COC=2C(=CC=CC=2)OC)CC1 SHHVHOCXTIVHRU-UHFFFAOYSA-N 0.000 description 1
- AXAKQVBGSXSMKT-UHFFFAOYSA-N n-(3,5-difluorophenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C=C(F)C=C(F)C=2)CC1 AXAKQVBGSXSMKT-UHFFFAOYSA-N 0.000 description 1
- JXKNPPZFZRSBDI-UHFFFAOYSA-N n-(4-aminophenyl)-n-butylacetamide Chemical compound CCCCN(C(C)=O)C1=CC=C(N)C=C1 JXKNPPZFZRSBDI-UHFFFAOYSA-N 0.000 description 1
- CHMBIJAOCISYEW-UHFFFAOYSA-N n-(4-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(N)C=C1 CHMBIJAOCISYEW-UHFFFAOYSA-N 0.000 description 1
- ZUYQCDVEEREVQY-UHFFFAOYSA-N n-(4-butylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide Chemical compound C1=CC(CCCC)=CC=C1NC(=O)CN1CCN(CC(O)COC=2C(=CC=CC=2)OC)CC1 ZUYQCDVEEREVQY-UHFFFAOYSA-N 0.000 description 1
- XDKFMQVYWMUAQE-UHFFFAOYSA-N n-(4-methylsulfinylphenyl)-2-piperazin-1-ylacetamide Chemical compound C1=CC(S(=O)C)=CC=C1NC(=O)CN1CCNCC1 XDKFMQVYWMUAQE-UHFFFAOYSA-N 0.000 description 1
- VSHTWPWTCXQLQN-UHFFFAOYSA-N n-butylaniline Chemical class CCCCNC1=CC=CC=C1 VSHTWPWTCXQLQN-UHFFFAOYSA-N 0.000 description 1
- RQGBYNFVMMJHHT-UHFFFAOYSA-N n-butylsulfanylaniline Chemical class CCCCSNC1=CC=CC=C1 RQGBYNFVMMJHHT-UHFFFAOYSA-N 0.000 description 1
- KEBXGLIHHLGNJH-UHFFFAOYSA-N n-methylsulfanylaniline Chemical class CSNC1=CC=CC=C1 KEBXGLIHHLGNJH-UHFFFAOYSA-N 0.000 description 1
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical class CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000005474 octanoate group Chemical class 0.000 description 1
- RAFYDKXYXRZODZ-UHFFFAOYSA-N octanoyl octanoate Chemical compound CCCCCCCC(=O)OC(=O)CCCCCCC RAFYDKXYXRZODZ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OSHVGUAPPIYWIS-UHFFFAOYSA-N piperazin-1-ium;acetate Chemical compound CC(O)=O.C1CNCCN1 OSHVGUAPPIYWIS-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DOKHEARVIDLSFF-UHFFFAOYSA-N prop-1-en-1-ol Chemical group CC=CO DOKHEARVIDLSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Pyridine Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS853492A CS246099B2 (cs) | 1983-05-18 | 1985-05-15 | Způsob výroby derivátů piperazinu |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/495,904 US4567264A (en) | 1983-05-18 | 1983-05-18 | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS246080B2 true CS246080B2 (en) | 1986-10-16 |
Family
ID=23970461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS843680A CS246080B2 (en) | 1983-05-18 | 1984-05-17 | Method of piperazine derivatives production |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4567264A (de) |
| EP (1) | EP0126449B1 (de) |
| JP (1) | JPS59219271A (de) |
| KR (1) | KR890000020B1 (de) |
| AT (1) | ATE31533T1 (de) |
| AU (1) | AU566489B2 (de) |
| BR (1) | BR1100474A (de) |
| CA (1) | CA1256874A (de) |
| CS (1) | CS246080B2 (de) |
| DE (1) | DE3468215D1 (de) |
| DK (1) | DK168535B1 (de) |
| ES (1) | ES532565A0 (de) |
| FI (1) | FI78479C (de) |
| HK (1) | HK91989A (de) |
| HU (1) | HU192404B (de) |
| IE (1) | IE57487B1 (de) |
| IL (1) | IL71863A (de) |
| MX (1) | MX9203001A (de) |
| NO (1) | NO163618C (de) |
| NZ (1) | NZ208188A (de) |
| PH (1) | PH20016A (de) |
| PL (2) | PL143558B1 (de) |
| PT (1) | PT78604B (de) |
| RU (2) | RU2071471C1 (de) |
| SG (1) | SG25086G (de) |
| ZA (1) | ZA843746B (de) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028610A (en) * | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
| ATE102931T1 (de) * | 1988-12-26 | 1994-04-15 | Kowa Co | Herstellung von glycidylaether. |
| ES2177601T3 (es) * | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| HU209723B (en) * | 1990-10-31 | 1994-10-28 | Richter Gedeon Vegyeszet | Process for producing of piperazine derivatives |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| EP0775128A1 (de) * | 1995-06-07 | 1997-05-28 | Dade Chemistry Systems Inc. | Verfahren zur herstellung von immunogenen und anderen arzneimittelkonjugaten |
| TWI245035B (en) * | 1998-06-26 | 2005-12-11 | Ono Pharmaceutical Co | Amino acid derivatives and a pharmaceutical composition comprising the derivatives |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| NZ520780A (en) * | 2000-02-18 | 2006-04-28 | Cv Therapeutics Inc | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| US6451798B2 (en) * | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| NZ520782A (en) * | 2000-02-22 | 2004-03-26 | Cv Therapeutics Inc | Substituted piperazine compounds that are partial fatty acid oxidation inhibitors |
| WO2001062711A2 (en) * | 2000-02-22 | 2001-08-30 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| AU2001238590A1 (en) * | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
| US6693099B2 (en) * | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| MXPA04000565A (es) * | 2001-07-19 | 2005-06-17 | Cv Therapeutics Inc | Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos. |
| US7001909B2 (en) * | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| EP2316468A1 (de) | 2002-02-22 | 2011-05-04 | Shire LLC | Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| AU2003248558B8 (en) | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| EP1517900B1 (de) | 2002-06-24 | 2009-05-27 | Janssen Pharmaceutica N.V. | Verfahren zur herstellung von n-(2,6-dimethylphenyl)-2-piperazin-1-ylacetamid |
| US7056924B2 (en) * | 2002-07-18 | 2006-06-06 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| ATE365737T1 (de) * | 2002-12-05 | 2007-07-15 | Cv Therapeutics Inc | Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren |
| EP1806346B1 (de) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation |
| NZ541069A (en) * | 2003-01-03 | 2008-09-26 | Cv Therapeutics Inc | Piperazine derivatives as fatty acid oxidation inhibitors |
| WO2004069818A1 (en) * | 2003-01-17 | 2004-08-19 | Cv Therapeutics Inc. | Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases |
| CA2530376A1 (en) * | 2003-06-23 | 2005-01-06 | Cv Therapeutics, Inc. | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| CA2550257A1 (en) | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| WO2006008753A1 (en) * | 2004-07-19 | 2006-01-26 | Unichem Laboratories Limited | Crystalline and amorphous form of ranolazine and the process for manufacturing them |
| US7271169B2 (en) * | 2004-09-08 | 2007-09-18 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| MX2007008162A (es) * | 2005-01-06 | 2007-07-24 | Cv Therapeutics Inc | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. |
| WO2008047388A2 (en) * | 2006-10-20 | 2008-04-24 | Ind-Swift Laboratories Limited | Improved process for the preparation of ranolazine |
| JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
| EP2117549A1 (de) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Verwendung von ranolazin zur behandlung koronarer mikrovaskulärer erkrankungen |
| CA2678272A1 (en) | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| WO2008109175A1 (en) * | 2007-03-07 | 2008-09-12 | Concert Pharmaceuticals, Inc. | Deuterated piperazine derivatives as anti-anginal compounds |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| WO2008139492A2 (en) * | 2007-05-15 | 2008-11-20 | Natco Pharma Limited | A process for the preparation of highly pure ranolazine base |
| RU2442585C2 (ru) * | 2007-05-31 | 2012-02-20 | Си Ви Терапьютикс, Инк. | Способ лечения диабета |
| CA2689633A1 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| KR20100047190A (ko) * | 2007-06-13 | 2010-05-07 | 오스펙스 파마슈티칼스, 인코포레이티드 | 치환 피페라진 |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| AR072196A1 (es) * | 2008-06-19 | 2010-08-11 | Medichem Sa | Procedimiento para preparar ranolazina purificada, util en el tratamiento cronico de la angina. |
| WO2010023687A2 (en) * | 2008-08-28 | 2010-03-04 | Shodhana Laboratories Limited | Preparation of ranolazine, its salts and intermediates thereof |
| WO2010025370A2 (en) * | 2008-08-28 | 2010-03-04 | Dr. Reddy's Laboratories Ltd. | Preparation of ranolazine |
| WO2010029436A2 (en) * | 2008-09-09 | 2010-03-18 | Actavis Group Ptc Ehf | Novel solid state forms of ranolazine salts |
| EP2356097A2 (de) * | 2008-10-15 | 2011-08-17 | Actavis Group PTC ehf. | Hochreines ranolazin oder pharmazeutisch unbedenkliches salz davon |
| WO2010097805A1 (en) | 2009-02-24 | 2010-09-02 | Lupin Limited | A process for the preparation of ranolazine |
| EP2515880B1 (de) | 2009-05-28 | 2019-11-27 | Lupin Limited | Neuartige pharmazeutische zusammensetzungen mit ranolazin |
| MX2012003362A (es) | 2009-09-25 | 2012-06-27 | Lupin Ltd | Composicion de liberación sostenida de ranolazina. |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
| NO3175985T3 (de) | 2011-07-01 | 2018-04-28 | ||
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| CN103570645A (zh) * | 2012-08-01 | 2014-02-12 | 上海迪赛诺化学制药有限公司 | 一种制备n-(2,6-二甲基苯基)-2-(1-哌嗪基)乙酰胺的方法 |
| EP3233814A4 (de) | 2015-03-10 | 2018-07-18 | Unichem Laboratories Limited | Neuartiges verfahren zur herstellung von ranolazin |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
| US12569481B2 (en) | 2020-06-12 | 2026-03-10 | Vanderbilt University | Methods of treatment for gastrointestinal motility disorders |
| CN119707868A (zh) * | 2023-09-27 | 2025-03-28 | 西安远大科创医药科技有限公司 | 一种盐酸维洛沙嗪产品杂质及其合成方法与应用 |
| CN118680891B (zh) * | 2024-08-20 | 2025-01-28 | 湖州亚瑟制药有限公司 | 一种用于治疗心绞痛的制剂组合物及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3360529A (en) * | 1962-01-29 | 1967-12-26 | Smith Kline French Lab | Guanidinoalkylbenzodioxan derivatives |
| US3829441A (en) * | 1962-01-29 | 1974-08-13 | Smith Kline French Lab | Guanidinoalkylbenzodioxan derivatives |
| US3496183A (en) * | 1964-11-19 | 1970-02-17 | Egyt Gyogyszervegyeszeti Gyar | Beta-guanidino-ethyl-piperazine derivatives |
| DE1795362A1 (de) * | 1968-09-19 | 1972-01-05 | Boehringer Mannheim Gmbh | Basische AEther und Verfahren zur Herstellung derselben |
| DE1795375A1 (de) * | 1968-09-21 | 1972-01-05 | Boehringer Mannheim Gmbh | Basische AEther und Verfahren zur Herstellung derselben |
| FR2154493B1 (de) * | 1971-09-13 | 1975-10-31 | Kali Chemie Ag | |
| GB1332008A (en) * | 1971-09-28 | 1973-10-03 | Pfizer Ltd | Piperazine derivatives their preparation and pharmaceutical compositions containing them |
| GB1374366A (en) * | 1972-07-21 | 1974-11-20 | Science Union & Cie | Propanol derivatives and a process for their preparation |
| GB1425559A (en) * | 1972-09-01 | 1976-02-18 | Wyeth John & Brother Ltd | Pyridine tetrahydropyridine and piperidine derivatives |
| GB1411531A (en) * | 1972-10-24 | 1975-10-29 | Lafon Labor | Amino derivatives of 1,4-benzodioxan |
| US3953448A (en) * | 1972-12-07 | 1976-04-27 | Delmar Chemicals Limited | Piperazino-anilido compounds |
| FR2267104A1 (en) * | 1974-04-12 | 1975-11-07 | Ferlux Labo Sa | Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines |
| FR2310763A1 (fr) * | 1975-05-13 | 1976-12-10 | Buzas Andre | Derives 1,4-disubstitues de la piperazine, leur procede de preparation et leurs applications |
| US4335126A (en) * | 1977-03-10 | 1982-06-15 | Degussa Aktiengesellschaft | 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity |
| FR2462432A2 (fr) * | 1979-08-03 | 1981-02-13 | Delalande Sa | Nouveaux derives de la 3,4,5 trimethoxy cinnamoyle piperazine, leur procede de preparation et leur application en therapeutique |
| FR2387971A1 (fr) * | 1977-04-19 | 1978-11-17 | Delalande Sa | Nouvelles trimethoxy cinnamoyles piperazines, leur procede de preparation et leur application en therapeutique |
| FR2456738A2 (fr) * | 1978-04-10 | 1980-12-12 | Delalande Sa | Nouvelles cinnamoyles piperazines et homopiperazines, leur procede de preparation et leur application en therapeutique |
| JPS6042795B2 (ja) * | 1978-10-23 | 1985-09-25 | 日本新薬株式会社 | カルバモイルピペラジン誘導体 |
| EP0025111B1 (de) * | 1979-08-10 | 1984-07-25 | Sandoz Ag | 3-Aminopropoxyaryl-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| DE2941597A1 (de) * | 1979-10-13 | 1981-04-23 | Basf Ag, 6700 Ludwigshafen | Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| GR71991B (de) * | 1980-01-21 | 1983-08-26 | Delalande Sa | |
| DE3005287A1 (de) * | 1980-02-13 | 1981-08-20 | Basf Ag, 6700 Ludwigshafen | Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel |
| US4302469A (en) * | 1980-09-10 | 1981-11-24 | Syntex (U.S.A.) Inc. | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants |
| US4684651A (en) * | 1981-03-17 | 1987-08-04 | Mitsubishi Chemical Industries Limited | Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives |
| US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| US4374837A (en) * | 1981-07-31 | 1983-02-22 | Laroche Navarron, S.A. | Piperazine derivatives of theobromine |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
-
1983
- 1983-05-18 US US06/495,904 patent/US4567264A/en not_active Expired - Lifetime
-
1984
- 1984-05-16 NO NO841968A patent/NO163618C/no not_active IP Right Cessation
- 1984-05-17 IL IL71863A patent/IL71863A/xx not_active IP Right Cessation
- 1984-05-17 CA CA000454628A patent/CA1256874A/en not_active Expired
- 1984-05-17 AU AU28346/84A patent/AU566489B2/en not_active Expired
- 1984-05-17 FI FI841989A patent/FI78479C/fi not_active IP Right Cessation
- 1984-05-17 NZ NZ208188A patent/NZ208188A/en unknown
- 1984-05-17 PL PL1984252856A patent/PL143558B1/pl unknown
- 1984-05-17 RU SU843741049A patent/RU2071471C1/ru active
- 1984-05-17 ES ES532565A patent/ES532565A0/es active Granted
- 1984-05-17 DK DK248384A patent/DK168535B1/da not_active IP Right Cessation
- 1984-05-17 PH PH30692A patent/PH20016A/en unknown
- 1984-05-17 PT PT78604A patent/PT78604B/pt unknown
- 1984-05-17 SG SG598/89A patent/SG25086G/en unknown
- 1984-05-17 EP EP84105643A patent/EP0126449B1/de not_active Expired
- 1984-05-17 ZA ZA843746A patent/ZA843746B/xx unknown
- 1984-05-17 KR KR1019840002696A patent/KR890000020B1/ko not_active Expired
- 1984-05-17 HU HU841902A patent/HU192404B/hu unknown
- 1984-05-17 DE DE8484105643T patent/DE3468215D1/de not_active Expired
- 1984-05-17 PL PL1984247722A patent/PL142760B1/pl unknown
- 1984-05-17 JP JP59097630A patent/JPS59219271A/ja active Granted
- 1984-05-17 CS CS843680A patent/CS246080B2/cs unknown
- 1984-05-17 AT AT84105643T patent/ATE31533T1/de not_active IP Right Cessation
- 1984-05-17 IE IE1224/84A patent/IE57487B1/en not_active IP Right Cessation
-
1989
- 1989-11-16 HK HK919/89A patent/HK91989A/en not_active IP Right Cessation
-
1991
- 1991-11-12 RU SU915001933A patent/RU2083570C1/ru active
-
1992
- 1992-06-18 MX MX9203001A patent/MX9203001A/es unknown
-
1997
- 1997-05-05 BR BR1100474-6A patent/BR1100474A/pt active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1256874A (en) | Cardioselective aryloxy and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium entry | |
| US4034009A (en) | 4-Ureido-2-acyl phenoxypropanolamine | |
| US4558129A (en) | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | |
| DK143128B (da) | Analogifremgan&smaade til fremstilling af 1-aryloxy-2-hydroxy-3-alkylaminopropaner eller deres fysiologisk acceptable syreadditionssalte | |
| EP0483932A1 (de) | Verfahren zur Herstellung von Piperazinderivaten | |
| US4067904A (en) | Alkylsulfonylphenoxypropanolamine derivatives | |
| US4631281A (en) | Substituted phenylpiperazinyl-propanols, a process for their preparation and their use, and formulations containing these compounds | |
| GB2046259A (en) | Amino-alcohol derivatives and pharmaceutical compositions containing them | |
| NO155880B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktivt 2-(2'hydroksy-3'-(1,1-dimetylpropylamino)-propoksy)-beta-fenylpropionfenon. | |
| US4075346A (en) | CNS depressant γ-(secondary amino)-ortho-nitro-butyrophenones | |
| DK151256B (da) | Analogifremgangsmaade til fremstilling af alkylendioxybenzenderivater | |
| FI62060B (fi) | Foerfarande foer framstaellning av beta-blockerande substituerad 2-hydroxi-3-(2-acyl-4-ureido-fenoxi)-propylaminderivat | |
| FR2460294A1 (fr) | Nouveaux oxime-ethers, leur procede de preparation et compositions pharmaceutiques les contenant | |
| JP4014643B2 (ja) | アリールオキシプロパノールアミン誘導体、その製造方法及びその用途 | |
| CS239948B2 (en) | Processing of substitute n-carboxamidealkylfenoxypropanolamine | |
| DK154021B (da) | Analogifremgangsmaade til fremstilling af phenoxy-aminopropanolderivater og epoxider til anvendelse som udgangsmateriale ved denne fremgangsmaade | |
| US5047425A (en) | Amine derivatives having cardiovascular activity | |
| CS255894B2 (en) | Process for preparing new derivatives of phenylacetonitrile | |
| US4259334A (en) | Piperazines and therapeutic utility | |
| CS246099B2 (cs) | Způsob výroby derivátů piperazinu | |
| TW467881B (en) | Guaiacoxypropanolamines with Α/β-adrenergic blocking activity | |
| US4119729A (en) | Alkylsulfonylphenoxypropanolamine therapeutic process | |
| US3983169A (en) | Phenoxypropylamine derivatives | |
| NO161736B (no) | Analogifremgangsmaate for fremstilling av nye derivater av1-alkylamin-3(4(p-alkyloksybenzamid)fenoksy)-2-propanol med beta-sympatolytisk aktivitet. | |
| CS207621B2 (en) | Method of making the derivatives of the alpha-methyl-beta-aminopropiophenon |